<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437177</url>
  </required_header>
  <id_info>
    <org_study_id>OH SPECT APO</org_study_id>
    <secondary_id>EudraCT: 2004-001893-24</secondary_id>
    <nct_id>NCT00437177</nct_id>
  </id_info>
  <brief_title>Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)</brief_title>
  <acronym>ALC-DRD2-APO</acronym>
  <official_title>Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence: Predictive Value for Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <brief_summary>
    <textblock>
      OH dependence is associated with DA receptor changes. Both, the apomorphine test and the
      D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA
      receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a
      marker of relapse in detoxified OH dependents patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To detertmine the agreement rate of the dopaminergic sensibility assessed by two different techiniques: the apomorphine test and and IBZM SPECT.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alcoholism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apomorphine</intervention_name>
    <description>Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[(123)I] iodobenzamide</intervention_name>
    <description>[(123)I] iodobenzamide 185 MBq I.V., at discharge.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  alcohol dependence

          -  alcohol dependence length at least 8 years.

          -  male

          -  age 25 - 60 years

        Exclusion Criteria:

          -  other drug dependence (except nicotine dependence)

          -  another major axis I psychiatric diagnosis

          -  comorbid neurological disorder

          -  comorbid cardiovascular disorder

          -  comorbid metabolic disorder

          -  brain injury

          -  apomorphine allergy

          -  iode allergy

          -  diazepam allergy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miquel Casas, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatry Service, Hospital Universitari Vall d'Hebron</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miquel Casas, Prof.</last_name>
    <email>mcasas@vhebron.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier Castells, Prof</last_name>
    <email>xcc@icf.uab.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psychiatry Service, Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miquel Casas, Prof</last_name>
      <email>mcasas@vhebron.net</email>
    </contact>
    <contact_backup>
      <last_name>Xavier Castells</last_name>
      <email>xcc@icf.uab.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Miquel Casas, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2007</study_first_submitted>
  <study_first_submitted_qc>February 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>m</name_title>
    <organization>Servei de Psiquiatria. Hospital Universitari Vall d'Hebron</organization>
  </responsible_party>
  <keyword>alcoholism</keyword>
  <keyword>apomorphine</keyword>
  <keyword>iodobenzamide</keyword>
  <keyword>imaging</keyword>
  <keyword>spect</keyword>
  <keyword>relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

